Biosimilars Clinical Research and Pharmacovigilance

Biosimilars Congress 2019 is included Keynote and Speakers sessions on the most recent examination intended to offer extensive worldwide exchanges that address current issues in Biosimilars Congress 2019

Biological medicines (biologics) have made considerable commitments to the treatment of numerous endless and genuine infections, for example, diseases, endless incendiary maladies and some uncommon hereditary scatters, and are anticipated that would give critical remedial advantages to numerous patients who would some way or another have had constrained treatment options. Post-endorsement pharmacovigilance is critical for biosimilars because of the idea of conditions they treat and the way that less patients are presented to a biologic amid formative clinical preliminaries.

·         Analysis of biosimilar products

·         Pharmacovigilance

·         Analysis of immunogenic responses

·         Risk Management Plan (RMP)

·         Requirement for Post-Approval Studies

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.